852391-39-0

Basic information

• Product Name: 1-(7-bromo-1H-indol-3-yl)-N,N-dimethylmethanamine
• Synonyms: 1-(7-bromo-1H-indol-3-yl)-N,N-dimethylmethanamine
• CAS NO: 852391-39-0
• Molecular Formula: C11H13BrN2
• Molecular Weight: 253.13832
• Mol File: 852391-39-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(7-bromo-1H-indol-3-yl)-N,N-dimethylmethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(7-bromo-1H-indol-3-yl)-N,N-dimethylmethanamine(852391-39-0)
• EPA Substance Registry System: 1-(7-bromo-1H-indol-3-yl)-N,N-dimethylmethanamine(852391-39-0)

Safety Data

• Hazardous Substances Data: 852391-39-0(Hazardous Substances Data)

Usage

Structure

A derivative of indole with a bromine atom at the 7th position, and a N,N-dimethylmethanamine group attached to the 1st position.

Pharmacological Properties

Potential serotonin receptor agonist

Applications

a. Scientific research
b. Medicinal chemistry
c. Chemical and biological research

Usage

Primarily in laboratory settings

Availability

Not widely available for commercial or industrial use

Purpose

To investigate the effects of indole derivatives on biological systems

Safety

Handle with care, as it is a chemical compound with potential pharmacological properties.

Upstream product

• 51417-51-7 7-bromo-1H-indole 
• 50-00-0 formaldehyd 
• 124-40-3 dimethyl amine 

Downstream Products

• 1044772-58-8 2-(7-bromo-1H-indol-3-yl)acetonitrile 
• 115666-21-2 7-bromo-1 H-indole-3-carbaldehyde 
• 732983-21-0 (+/-)-7-bromotryptophan methyl ester 
• 852391-45-8 DL-7-Bromo-tryptophan 

Relevant articles and documents

Discovery of the cancer cell selective dual acting anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131)

Selective targeting of cancer cells over normal cells is a key objective of targeted therapy. However few approaches achieve true mechanistic selectivity resulting in debilitating side effects and dose limitation. In this work we describe the discovery of A131 (4a), a new agent with an unprecedented dual mechanism of action targeting both mitosis and autophagy. Compound 4a was first identified in a phenotypic screen in which HeLa cells treated with 4a manifested mitotic arrest along with formation of multiple vesicles. Further investigations showed that 4a causes an increase in mitotic marker pH3 and autophagy marker LC3. Importantly 4a induces cell death in cancer cells while sparing normal cells which regrow after 4a is removed. Dual activities against pH3 and LC3 markers are required for cancer cell selectivity. An extensive SAR investigation confirmed 4a as the optimal dual inhibitor with potency against a panel of 30 cancer cell lines (average antiproliferative GI50 1.5 μM). In a mouse model of paclitaxel-resistant colon cancer, 4a showed 74% tumor growth inhibition when administered at a dose of 20 mg/kg IP twice a day.

Inhibitors of cellular necrosis

The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis.